New assays for parathyroid hormone (PTH) and the relevance of PTH fragments in renal failure Management of comorbidities in kidney disease in the 21st century: Anemia and bone disease by Goodman, William G.
Kidney International, Vol. 64, Supplement 87 (2003), pp. S120–S124
New assays for parathyroid hormone (PTH) and the relevance
of PTH fragments in renal failure
WILLIAM G. GOODMAN
Department of Medicine, Division of Nephrology, UCLA School of Medicine, Los Angeles, California
New assays for parathyroid hormone (PTH) and the relevance
of PTH fragments in renal failure.
Background. Immunometric assays for parathyroid hor-
mone (PTH) are used extensively to assess bone and mineral
metabolism in patients with end-stage renal disease (ESRD)
who are treated with dialysis. Results generally correspond to
bone histology as documented by bone biopsy, and they are
useful in monitoring disease progression. Recent work has
shown, however, that older, first-generation immunometric
PTH assays detect not only full-length PTH(1-84), but also
other amino-terminally-truncated PTH fragments (ntPTH)
that may have inhibitory effects on bone cell metabolism and/or
contribute to the development of adynamic renal osteodystro-
phy. New second-generation immunometric PTH assays, by
contrast, detect PTH(1-84) exclusively. The diagnostic value
of plasma PTH determinations using second-generation immu-
nometric PTH assays and the utility of estimates of the concen-
tration of ntPTH in plasma in patients with ESRD has been
assessed only recently.
Methods. Results were reviewed from three published stud-
ies that examined the relationship between bone histology and
plasma PTH levels as measured both by first- and by second-
generation immunometric PTH assays in patients with ESRD.
In all three studies, the concentration of ntPTH was estimated
from the numerical difference between the results obtained
with each assay and a ratio of PTH(1-84)/ntPTH was calculated.
Results. In one report, all patients with adynamic renal os-
teodystrophy had PTH(1-84)/ntPTH ratio values 1.0, al-
though some patients with high-turnover skeletal lesions also
had values 1.0. Estimates of the ratio of PTH(1-84)/ntPTH
were found to be a better predictor of adynamic bone than
PTH values measured by either assay. By contrast, two other
studies failed to confirm these observations. One made use of
the same second-generation immunometric PTH assay em-
ployed in the original report, whereas the other used a different
assay with similar specificity for PTH(1-84). Plasma PTH levels
obtained by first- and second-generation assays were highly
correlated in these two independent reports.
Conclusion. Plasma PTH levels, as determined by first-gener-
ation and second-generation immunometric assays, are highly
correlated and have similar diagnostic value for the non-inva-
sive assessment of renal osteodystrophy. The contention that
ntPTH estimates and values for the PTH(1-84)/ntPTH ratio
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are useful in the diagnostic assessment of renal osteodystrophy
has yet to be confirmed.
Immunometric assays for parathyroid hormone (PTH)
have been used extensively for the past 15 to 20 years
to assess bone and mineral metabolism in patients with
chronic kidney disease [1]. These double antibody sand-
wich-type assays circumvent many of the shortcomings
of single-antibody radioimmunoassays (RIAs) used pre-
viously, thus making it possible to obtain reliable and
reproducible measurements of the concentration of PTH
in serum or plasma in those with end-stage renal disease.
Several studies of large numbers of patients using quanti-
tative bone histomorphometry and tetracycline-based
measurements of bone formation have demonstrated
that plasma PTH levels, as determined by immunometric
assays, are generally reliable predictors of bone histology
and the underlying type of renal osteodystrophy in pa-
tients undergoing either hemodialysis or peritoneal dial-
ysis [2–7]. Accordingly, plasma PTH measurements are
employed extensively not only for the initial diagnosis
of renal bone disease but also to monitor its evolution
because bone biopsy is not used commonly in routine
clinical practice.
Despite these findings, certain therapeutic interven-
tions such as the use of large intermittent doses of
calcitriol or other active vitamin D sterols to treat sec-
ondary hyperparathyroidism and the use of large oral
doses of calcium as a phosphate-binding agent can dis-
rupt the relationship between plasma PTH levels and
the rates of bone formation and turnover in patients with
end-stage renal disease [8, 9]. Moreover, recent reports
have led to considerable uncertainty among clinicians
about the overall validity of plasma PTH measurements
for the diagnosis and management of renal osteodystro-
phy [10, 11]. In part, some of these difficulties are related
to the introduction of new immunometric PTH assays,
which differ fundamentally from those utilized pre-
viously, providing substantially different numerical re-
sults [12]. Controversy persists, however, about the bio-
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logical significance of several large peptide fragments of
PTH that are present in the circulation both in normal
subjects and in those with renal failure. Some of these
peptides have been shown to influence bone cell function
and may thus affect skeletal metabolism, but their impor-
tance as modifiers of bone formation and turnover in
patients with renal bone disease remains uncertain [11].
Technical details about new immunometric assays for
PTH and their use in the clinical management of patients
with chronic renal failure are the primary focus of the
current discussion. The role of PTH fragments as poten-
tial modifiers of bone metabolism in chronic renal failure
is also addressed.
EVOLUTION OF PTH ASSAYS
RIA methods were used almost exclusively in early
PTH assays [13, 14]. These systems employed single anti-
bodies directed at epitopes located in the mid- or car-
boxy-terminal regions of the hormone in competitive
displacement assays with isotopically labeled peptides,
usually highly purified full-length PTH or synthetic PTH
fragments. Because the portions of the molecule targeted
by these antibodies were some distance from the amino-
terminal end, most RIAs for PTH cross-reacted with, and
thus detected a variety of amino-terminally-truncated
PTH-derived peptides, or carboxy-terminal fragments,
as well as the full-length hormone comprised of 84 amino
acids, or PTH(1-84).
Most, if not all, amino-terminally-truncated PTH frag-
ments have generally been thought to lack biological
activity because they do not contain the amino-terminal
portion of the hormone responsible for binding to and
activating the type 1 PTH receptor, or PTH1R. Some of
these peptide fragments arise from the degradation of
PTH(1-84) within parathyroid cells, whereas others are
generated by the metabolism of PTH(1-84) in peripheral
tissues, most notably liver [15, 16]. They are removed
from the circulation predominantly by glomerular filtra-
tion and thus accumulate in the plasma of patients with
renal failure [16–18]. Because these peptide fragments
were detected by conventional RIAs for PTH, plasma
PTH values were commonly elevated, frequently mark-
edly so, in patients with end-stage renal disease. Mea-
surements often were not reproducible, and values failed
to consistently predict the underlying type of renal bone
disease [19, 20].
The subsequent development of immunometric PTH
assays made it possible to reliably and reproducibly mea-
sure the concentration of PTH in serum or plasma in
patients with end-stage renal disease [1, 21]. These assays
utilize two antibodies directed toward distinct epitopes
in different portions of the PTH molecule. One antibody,
which is tagged with 125I or a chemiluminescent agent,
serves to label peptides that are immobilized for quanti-
tation by a second capture antibody attached to a solid
phase such as a plastic bead. Only large peptides capable
of interacting with both antibodies, presumably PTH(1-
84), are measured in immunometric PTH assays. Small
peptides that lack one or both targeted epitopes are not
detected.
Until recently, immunometric PTH assays were thought
to detect predominantly full-length, biologically active
PTH(1-84). It is now apparent, however, that several
widely utilized immunometric PTH assays detect one or
more peptides distinct from PTH(1-84) [12, 22, 23]. Some
of these run on high-performance liquid chromatography
at the same position as synthetic PTH(7-84) [22, 24, 25].
Thus, first-generation immunometric PTH assays overes-
timate the concentration of PTH(1-84) in serum or plasma.
In contrast, recently developed second-generation im-
munometric PTH assays measure PTH(1-84) exclusively
and do not detect large amino terminally truncated pep-
tides such as synthetic PTH(7-84). The specificity of sec-
ond-generation immunometric PTH assays for PTH(1-
84) is determined by labeling antibodies that are directed
toward epitopes located in the most amino-terminal por-
tion of the molecule [12]. Indeed, the capacity for de-
tecting synthetic human PTH(1-34) by the labeling anti-
body used in one second-generation immunometric PTH
assay is eliminated almost completely by deleting the
first amino acid residue.
The ability to measure PTH(1-84) specifically and ex-
clusively represents an important technical advance. Sec-
ond-generation immunometric PTH assays should thus
prove to be useful in studies designed to better character-
ize the physiology of PTH secretion and hormone metab-
olism. Ultimately, they may also provide better diagnos-
tic discrimination in certain clinical disorders of bone
and mineral metabolism, but sufficient data to address
these issues are not yet available.
The impact of recent advances in PTH assay methods
on the diagnosis and management of patients with renal
osteodystrophy remains to be determined. It is not yet
known whether second-generation immunometric PTH
assays provide additional diagnostic information com-
pared to first-generation assays in the biochemical assess-
ment of patients with renal osteodystrophy. Consider-
able additional work will be required to address this
issue.
Despite the limitations of currently available data, sev-
eral reports indicate that plasma PTH values obtained
using second-generation immunometric assays are highly
correlated with values determined by first-generation
assays [12, 23, 26]. Although there is some variation
among assays from different commercial sources, avail-
able results indicate that plasma PTH levels measured
by second-generation immunometric PTH assays are ap-
proximately 40% to 50% lower than those determined
using first-generation assays across a wide range of
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plasma PTH concentrations [11, 12, 23, 26]. Such findings
suggest that PTH(1-84) represents slightly more than
half of the immunoreactivity detected by first-generation
immunometric PTH assays. The remainder of the immu-
noreactivity detected in first-generation PTH assays re-
flects the presence of a variety of amino terminally trun-
cated peptide fragments.
PTH MEASUREMENTS AND BONE
METABOLISM IN RENAL FAILURE
The utility of PTH measurements for the diagnosis
and management of bone disease in patients with end-
stage renal disease depends largely on the extent to
which results have been validated by bone histomorpho-
metry. Abundant quantitative histologic data are avail-
able from clinical studies of renal osteodystrophy using
first-generation immunometric PTH assays, but rela-
tively little information is available using second-genera-
tion immunometric assays that measure PTH(1-84) ex-
clusively. As such, the diagnostic value of recently
introduced immunometric PTH assays has yet to be de-
termined.
When measured by first generation immunometric
assays, plasma PTH levels generally predict the underly-
ing type of renal bone disease in patients with end-stage
renal disease who have not been treated with vitamin D
sterols or who are receiving small daily oral doses of
vitamin D, specifically calcitriol [2–7]. Values two- to
four-fold above the upper limit of normal correspond to
relatively normal rates of bone formation as documented
by the technique of double tetracycline labeling in bone
biopsy specimens. For the most widely utilized first-gen-
eration immunometric assays, plasma PTH levels in pa-
tients with normal rates of bone formation usually range
from 150 to 250 pg/mL, or 15 to 25 pmol/L. Higher levels
are seen in those with bone biopsy evidence of secondary
hyperparathyroidism, whereas plasma PTH concentra-
tions below 150 pg/mL, or 15 pmol/L, suggest the presence
of adynamic renal osteodystrophy. Plasma PTH levels less
than 100 pg/mL, or 10 pmol/L, provide even stronger
biochemical evidence of adynamic bone, particularly if
serum calcium concentrations are also elevated [3].
It should be recognized, however, that most reports
describing the relationship between plasma PTH levels
and bone histology in patients with end-stage renal dis-
ease antedate the use of large, intermittent intravenous
doses of vitamin D to treat secondary hyperparathyroid-
ism [2–7]. As such, these somewhat dated results may
not accurately reflect the consequences of current thera-
peutic strategies on bone formation and turnover in pa-
tients with secondary hyperparathyroidism. Large, inter-
mittent doses of calcitriol and the use of large oral doses
of calcium to manage phosphorus retention have each
been implicated as causes of adynamic renal osteodystro-
phy. Both therapeutic interventions reduce osteoblastic
activity and diminish bone formation in patients under-
going long-term dialysis [8, 9, 27, 28]. Indeed, bone for-
mation may decrease substantially in some patients with
secondary hyperparathyroidism who are treated with
large intermittent doses of calcitriol even though plasma
PTH levels remain as high as 400 or 500 pg/mL, or 40
or 50 pmol/L [8].
The mechanisms responsible for the disparity between
plasma PTH levels and bone formation during intermit-
tent calcitriol therapy remain uncertain. It may, however,
reflect direct inhibitory actions of vitamin D, either alone
or together with vitamin D–associated changes in cal-
cium metabolism, on osteoblastic function [8, 9, 27, 28].
Such observations underscore the importance of more
precisely defining the relationship between plasma PTH
levels and bone formation within specific therapeutic
contexts. Although PTH is the predominant regulator
of bone formation and turnover in patients with end-
stage renal disease, other factors also affect osteoblastic
activity through PTH-independent pathways [8, 9, 27–
29]. Thus, diabetes mellitus, corticosteroid therapy, os-
teoporosis, bone aluminum toxicity, and growth hor-
mone therapy each directly affect osteoblastic activity
and bone formation. Failure to adequately consider these
issues may partially account for results from studies that
challenge the diagnostic value of first-generation immu-
nometric PTH assays as predictors of bone histology in
patients with end-stage renal disease [10].
Three reports have examined the relationship between
bone histology and plasma PTH levels as determined by
first-generation and second-generation PTH assays in
patients with renal osteodystrophy [11, 30, 31]. Although
neither PTH assay was shown to be superior as a pre-
dictor of bone histology and bone turnover, technical
differences between first- and second-generation PTH
assays were used in all three studies to estimate the
concentration of amino terminally truncated PTH pep-
tides in plasma. Several reports indicate that amino ter-
minally truncated PTH peptides exert inhibitory effects
on osteoblasts and other bone cells [32, 33]. Moreover,
the accumulation of excess amounts of these peptides has
been suggested to contribute to the skeletal resistance to
PTH that characterizes end-stage renal disease, possibly
by interacting with a putative C-PTH receptor, distinct
from PTH1R, which is capable of high-affinity binding
to mid- and/or carboxyterminal regions of the PTH mole-
cule [11, 26].
To examine the potential clinical relevance of these
observations, the concentration of amino terminally
truncated PTH fragments (ntPTH) in plasma was esti-
mated by subtracting PTH values obtained using a sec-
ond-generation immunometric PTH assay, which detects
PTH(1-84) exclusively, from those determined by a first-
generation immunometric PTH assay that detects both
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PTH(1-84) and other relatively large amino terminally
truncated PTH-derived fragments. A ratio depicting the
relative abundance of biologically active PTH(1-84) and
PTH fragments was also calculated and expressed as
PTH(1-84)/ntPTH [11].
In a study of 51 patients with end-stage renal disease,
Monier-Faugere et al [11] reported that the PTH(1-84)/
ntPTH ratio was a better predictor of adynamic renal
osteodystrophy than plasma PTH values measured by
either first-generation or second-generation PTH assays.
All patients with adynamic bone had PTH(1-84)/ntPTH
values1, although some individuals with high-turnover
skeletal lesions of secondary hyperparathyroidism also
had PTH(1-84)/ntPTH ratio values that were1. In con-
trast, Coen et al [30] found no relationship between
values for the PTH(1-84)/ntPTH ratio and bone histol-
ogy among 35 patients undergoing regular hemodialysis.
Values for the PTH(1-84)/ntPTH ratio did not differ
among patients with various histologic subtypes of renal
osteodystrophy, and the results failed to selectively iden-
tify patients with adynamic renal osteodystrophy [30].
Similar results were reported by Salusky et al [31] using
a different second-generation immunometric PTH assay.
As such, the contention that values for the PTH(1-84)/
ntPTH ratio and/or estimates of the abundance of ntPTH
in plasma affect bone metabolism in patients with renal
osteodystrophy remain unsubstantiated.
Overall, currently available data indicate that second-
generation immunometric PTH are similar to first-gen-
eration PTH assays in their capacity to discriminate
between patients with high-turnover or low-turnover
skeletal lesions of renal osteodystrophy. The diagnostic
precision of new PTH assays has not yet been shown
to be greater than previously employed immunometric
assays in patients with renal bone disease. Results ob-
tained using first- and second-generation immunometric
PTH assays are highly correlated, and the slope of this
relationship ranges from approximately 0.5 to 0.6. Thus,
values determined by second-generation immunometric
PTH assays are usually 50% to 60% of those measured
by first-generation assays. It is possible, therefore, to
estimate plasma PTH values that would be expected
using second-generation immunometric assays in pa-
tients with various subtypes of renal osteodystrophy
based upon available data using first-generation immu-
nometric PTH assays.
The recommended therapeutic target range of 150 to
250 pg/mL, or 15 to 25 pmol/L, in patients with end-
stage renal disease and relatively normal rates of bone
formation as determined by first-generation immunome-
tric PTH assays should correspond to values of approxi-
mately 75 to 125 pg/mL as measured by second-genera-
tion assays. Slightly higher values would be expected if
the slope of the linear correlation between first- and
second-generation PTH assays were somewhat greater
[30]. Values above 125 to 150 pg/mL using second-gener-
ation PTH assays are likely to be associated with skeletal
changes of secondary hyperparathyroidism, whereas lev-
els below 50 to 75 pg/mL would be expected in patients
with adynamic renal osteodystrophy. More definitive
statements about the relationship between plasma PTH
levels as determined by second-generation immunome-
tric PTH assays and bone histology in patients with end-
stage renal disease must await the results of additional
studies.
CONCLUSION
New second-generation immunometric PTH assays
have been developed. The assays measure full-length
biologically active PTH(1-84) exclusively and do not de-
tect amino terminally truncated PTH fragments, a fea-
ture that distinguishes them from first-generation immu-
nometric PTH assays. Although only a few studies have
been done, second-generation immunometric PTH assays
have not been shown to be superior to first-generation
assays for the diagnostic assessment of patients with re-
nal osteodystrophy. Plasma PTH levels obtained using
first-generation immunometric PTH assays thus provide
the most definitive guide to the management of renal
bone disease because they are supported by abundant
bone histology data. Additional work is needed to fur-
ther characterize the utility of second-generation immu-
nometric PTH assays as predictors of bone histology in
patients with end-stage renal disease.
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